华润双鹤: 华润双鹤简式权益变动报告书

Core Viewpoint - The report outlines a non-compensatory transfer of state-owned equity from China Resources Pharmaceutical Investment Co., Ltd. to China Resources Pharmaceutical Holdings Co., Ltd., resulting in a change in the controlling shareholder of Beijing Pharmaceutical Group without altering the actual controller, which remains China Resources [1][5]. Group 1: Company Information - The listed company is China Resources Double Crane Pharmaceutical Co., Ltd., with stock code 600062 and listed on the Shanghai Stock Exchange [4]. - The information disclosure obligor is China Resources Pharmaceutical Investment Co., Ltd., a wholly-owned subsidiary of China Resources Pharmaceutical Holdings [4][6]. Group 2: Equity Change Details - The equity change involves a non-compensatory transfer of 51% of the shares of Beijing Pharmaceutical Group from China Resources Pharmaceutical Investment to China Resources Pharmaceutical Holdings [6]. - Following this transfer, China Resources Pharmaceutical Investment will no longer hold any shares in the listed company, while China Resources Pharmaceutical Holdings will hold 319,155,768 shares, representing 30.72% of the total share capital [9]. Group 3: Regulatory Compliance - The report complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Measures for the Administration of Acquisitions of Listed Companies [1][2]. - The report confirms that there are no other means of increasing or decreasing the shareholding in China Resources Double Crane Pharmaceutical Co., Ltd. apart from what is disclosed [1].